Alpha N-Acetyl Galactosaminidase (Schindler disease)

The Alpha N-Acetyl Galactosaminidase (Schindler disease) test measures the activity of alpha-N-acetylgalactosaminidase, a lysosomal enzyme involved in breaking down particular complex sugar-containing molecules. Deficiency of this enzyme is associated with Schindler disease, a very rare inherited lysosomal storage disorder caused by disease-causing variants in the NAGA gene. Reduced enzyme activity allows specific glycoproteins, glycolipids and related substances to accumulate within cells, potentially affecting the nervous system, skin, eyes, hearing and other organs.

Schindler disease can produce a wide spectrum of clinical findings. Severe forms may begin during infancy and cause progressive neurological problems, while milder forms may present later with skin lesions and less prominent neurological involvement. An intermediate form with variable symptoms has also been described. Because the disorder is exceptionally rare and its symptoms can resemble those of other metabolic or neurological conditions, biochemical enzyme testing is an important part of the diagnostic assessment.

Benefits of the Test

• Measures alpha-N-acetylgalactosaminidase enzyme activity.
• Helps investigate suspected Schindler disease or Kanzaki disease.
• Supports the evaluation of unexplained neurological, developmental or skin abnormalities.
• Provides biochemical evidence that can guide NAGA gene analysis.
• May assist with testing relatives after a diagnosis is confirmed in a family.
• Helps distinguish this enzyme deficiency from other lysosomal storage disorders.

Why Doctors Recommend This Test

A metabolic specialist, neurologist, paediatrician or geneticist may recommend the test when a patient's symptoms suggest an inherited lysosomal disorder. Depending on the form and severity of the condition, possible findings can include developmental delay, loss of previously acquired skills, seizures, reduced muscle tone, muscle weakness, movement abnormalities, intellectual disability, vision or hearing problems and progressive neurological deterioration. Some individuals develop clusters of small, dark-red skin lesions known as angiokeratomas, characteristic facial features, reduced sweating or other systemic abnormalities.

The clinical presentation alone cannot establish a diagnosis because these features overlap with several other genetic and metabolic conditions. Demonstration of significantly reduced alpha-N-acetylgalactosaminidase activity can provide important biochemical evidence. The result is generally confirmed through molecular analysis of the NAGA gene. Additional biochemical or genetic tests may be requested to exclude disorders with similar manifestations.

Preparation Before Test

Fasting is usually not required unless the referring doctor or laboratory gives specific instructions. Inform the healthcare team about current medicines, supplements, recent blood transfusions and any known family history of neurological disease, metabolic disease or Schindler disease. The enzyme may be measured using leukocytes, plasma, cultured fibroblasts or another validated specimen, depending on the laboratory method. Correct collection, storage and transportation are essential because enzyme activity can be affected by inappropriate sample handling.

Normal Reporting Time

This is a highly specialized enzyme assay and is not usually processed like a routine biochemistry test. Results may require several working days or longer depending on the specimen, testing schedule, transportation, quality checks and whether repeat or confirmatory analysis is necessary. Focus Diagnostics will provide the applicable turnaround estimate at the time of sample collection.

Who Should Take This Test?

• Infants or children with unexplained developmental delay or neurological regression.
• Patients with seizures, muscle weakness or other progressive neurological abnormalities.
• Individuals with angiokeratomas and findings suggestive of a lysosomal storage disorder.
• People with a family history of confirmed Schindler disease or NAGA gene variants.
• Patients referred by a geneticist or metabolic specialist after abnormal screening results.
• Relatives requiring targeted evaluation following an established family diagnosis.

Detailed Information

Schindler disease follows an autosomal recessive inheritance pattern. An affected individual usually inherits one disease-causing NAGA gene variant from each parent. Parents who carry a single variant generally do not develop the disease but can pass the variant to their children. When both parents are carriers, each pregnancy has a 25% probability of an affected child, a 50% probability of a carrier child and a 25% probability of a child who inherits neither familial variant.

Enzyme activity must be interpreted using the reference interval and specimen type specified by the testing laboratory. Markedly reduced activity may support alpha-N-acetylgalactosaminidase deficiency, but the result should not be considered alone. Molecular genetic testing is important for confirmation, classification and family counselling. If a diagnosis is established, the doctor may recommend neurological assessment, developmental evaluation, eye and hearing examinations, skin assessment, imaging studies and other organ-specific investigations.

There is currently no single routine curative treatment for all forms of Schindler disease. Care is individualized and may include seizure management, nutritional assistance, physical and occupational therapy, developmental support, treatment of specific complications and regular specialist monitoring. Genetic counselling can help families understand inheritance, carrier testing and reproductive options. All enzyme and genetic results should be discussed with a qualified specialist familiar with inherited metabolic disorders.